NCT03114943View on ClinicalTrials.gov

Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age

PHASE3CompletedINTERVENTIONAL

Enrollment

516

Participants

Timeline

Start Date

July 14, 2016

Primary Completion Date

June 28, 2017

Study Completion Date

June 28, 2017

Conditions

Varicella

Interventions

BIOLOGICAL

NBP608

Preparation of the Oka/SK strain of live, attenuated varicella virus

BIOLOGICAL

Varivax

Preparation of the Oka/Merck strain of live, attenuated varicella virus

Trial Locations (1)

4114

De La Salle Health Sciences Institute, Dasmariñas

All Listed Sponsors

lead

SK Bioscience Co., Ltd.

INDUSTRY

NCT03114943 - Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age | Biotech Hunter | Biotech Hunter